RCAP
MLYS icon

Resolute Capital Asset Partners’s Mineralys Therapeutics MLYS Stock Holding History

Resolute Capital Asset Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,000
Closed -$1.52M – 61
2025
Q3 		$1.52M Buy
+40,000
New +$865K 0.79% 38

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Resolute Capital Asset Partners's MLYS Position: Q4 2025 in Review

Resolute Capital Asset Partners sold out of Mineralys Therapeutics (MLYS) in Q4 2025, closing a stake of 40,000 shares — an estimated $1.52M sold.

Resolute Capital Asset Partners first reported a position in MLYS in Q3 2025 and held it in 1 quarter. The position peaked at $1.52M in Q3 2025. 223 funds tracked by Wall St. Rank hold MLYS as of Q4 2025.

  • Resolute Capital Asset Partners reported no remaining Mineralys Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Resolute Capital Asset Partners sold 40,000 Mineralys Therapeutics shares in Q4 2025, an estimated $1.52M.
  • Resolute Capital Asset Partners first reported a position in Mineralys Therapeutics in Q3 2025 and held it in 1 quarter.
  • Resolute Capital Asset Partners's Mineralys Therapeutics position peaked at $1.52M in Q3 2025.
  • 223 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2025.

Based on Resolute Capital Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.